STAT+: NIH confirmation hearing highlights just how divisive the agency’s portfolio has become
Monica Bertagnolli, President Biden’s nominee to lead the National Institutes of Health, spent her confirmation…
Author: STAT
STAT+: In drug development, large pharma companies’ staying power provides them an edge, Lilly’s chief medical officer says
Among drugmakers, big pharma has a reputation of being stodgy and old-fashioned, while biotech startups…
STAT+: Biotech investors push to extend time before pills are subject to price negotiations
The fight over drug prices is far from over. Investors in biopharma companies, who lobbied…
Wegovy doesn’t work for everyone, and no one’s quite sure why
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Biotech investors push to extend time before Medicare price negotiations; RiteAid closings could cause pharmacy deserts
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Why doesn’t everyone lose weight on Ozempic-type drugs? Researchers look for genetic clues
DALLAS — Treatments like Ozempic, Wegovy, and Mounjaro have been hailed for showing 15% to…
STAT+: The Ozempic panic: Why a market frenzy over new weight loss drugs defies logic
There’s a specter haunting Wall Street. It started in biotech, where companies making drugs for…
STAT+: In an unusual arrangement, UnitedHealth’s board chair also owns a personal investment firm
Stephen Hemsley, the former CEO of UnitedHealth Group and its current board chair, also owns…
Opinion: Listen: Why long Covid might predate the pandemic
Since the early days of the pandemic, long Covid has haunted us: Even a mild…
.jpg)
Opinion: STAT+: Preventive drugs may be the best solution to the antibiotic resistance crisis
The antibiotics crisis is a silent pandemic that threatens to knock modern society back into…
.jpg)
STAT+: Revenue cycle management company Waystar files for IPO
Revenue cycle management company Waystar filed for an initial public offering Monday with the Securities…
STAT+: It’s time for the FDA to halt Cassava Sciences’ Alzheimer’s clinical trials
The Food and Drug Administration should halt Cassava Sciences’ ongoing clinical trials in Alzheimer’s disease….
Breast cancer is deadlier for Black women. A study of mammograms could help close the gap
Are 3D mammograms better than standard 2D imaging for catching advanced cancers? A clinical trial is recruiting…
STAT+: When Medicare paid doctors differently, fewer patients had heart problems
WASHINGTON — Doctors lowered the incidence of heart disease and strokes among their patients when…
As Pfizer slashes revenue projections, Moderna says it “remains comfortable”
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: People with obesity harmed by exclusion from studies; Teva sues Colorado over ‘unconstitutional’ program
Rise and shine, everyone, another busy day is on the way. We can tell, in…
Measuring the long-term cost of restricting abortion access
When Diana Greene Foster and her team at the University of California, San Francisco, started…
STAT+: Our expensive obesity drugs are worth it, Novo Nordisk and Eli Lilly argue in raft of studies
DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and…
STAT+: How one scientist’s determination made Novo Nordisk an obesity-drug powerhouse
Lotte Bjerre Knudsen was still getting used to all the empty benches in her lab…
Watch: A conversation with the 2023 STAT Wunderkinds
Each year, STAT sets out to celebrate the unheralded heroes of science and medicine, poring…
STAT+: White House moves closer to a ban on menthol cigarettes, amid intensifying opposition from tobacco companies
WASHINGTON — The White House is about to feel what it’s like to go up…
Studies highlight risks of excluding people with obesity from drug trials
People with obesity often go underrepresented in drug development trials, a critical gap that researchers…
STAT+: Teva sues Colorado over ‘unconstitutional’ program to lower cost of epinephrine injectors
In the latest tussle over the cost of medicines, Teva Pharmaceuticals has filed a lawsuit…
Serotonin levels are depleted in long Covid patients, study says, pointing to a potential cause for ‘brain fog’
If you’ve been following the mystery of long Covid since it emerged in 2020, you’ll…
Candor on gene therapy, Abiomed is warned, & BTK success in MS
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Rite Aid files for bankruptcy; Alzheimer’s brain scans get broader Medicare coverage
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Cell and gene therapy CEOs share survival strategies amid biotech slump
CARLSBAD, Calif. — Biotech CEOs leading cell and gene therapy companies spoke frankly at a…
STAT+: FDA’s warning to J&J’s Abiomed signals a crackdown on digital health tools
The Food and Drug Administration is following through on its promise to regulate more health…
Opinion: Doctors — and patients — must seek alternatives to long-term steroids
Steroids were once the only treatment option for some chronic conditions. Today, many other treatments…
Is there a nursing shortage in the United States? Depends on who you ask
Hospitals are frustrated with a nationwide nursing shortage that’s only gotten worse since the pandemic….
STAT+: Dana-Farber’s divorce from Brigham is the culmination of decades of change
On the Southeast Expressway, at the edge of the city, two billboards advertising cancer care…
STAT+: What to know about this year’s Medicare open enrollment period
It’s the middle of October — the time of year that’s filled with pumpkin spice…
Opinion: Why Gaza health care facilities and workers have suffered so much violence
In a mere week, the fifth major conflict in the past 15 years between Hamas…
STAT+: Eye docs urge Medicare to lower insurance hurdles amid shortage of repackaged Avastin
Due to a shortage of a widely used compounded medicine for serious eye diseases, two…
STAT+: UnitedHealth’s profit jumps as medical costs come in lower than expected
UnitedHealth Group has made it clear that more people, especially older adults, are seeing their…
STAT+: HHS dispatches millions to next-generation Covid targets, including intranasal vaccine
WASHINGTON — The Biden administration announced Friday that it is investing in three potential vaccines…
Vampiric cancer cells, a brain atlas, & alleged misconduct at Cassava
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Medicare to cover more brain scans related to Alzheimer’s drugs
Medicare has officially expanded its coverage policy for brain scans that detect a brain plaque…
Kaiser Permanente reaches tentative agreement with workers
After a historic strike, healthcare giant Kaiser Permanente and the Coalition of Kaiser Permanente Unions…
STAT+: Amgen reports first clinical data on new targeted cancer therapy
It’s been a busy week for a cancer drug target called PRMT5 that may play…
STAT+: Pharmalittle: Makers of toxic cough syrups face new actions; Cassava suffers new blow over Alzheimer’s drug
And so, another working week will soon draw to a close. Not a moment too…
STAT+: European regulators once again recommend Amylyx’s ALS drug be rejected
LONDON — European regulators on Friday reiterated their view that an ALS treatment from Amylyx…
He was named a MacArthur ‘genius’ fellow for research on gene regulation, but still has imposter syndrome
The youngest of this year’s class of MacArthur “genius grant” fellows, 35-year-old Jason Buenrostro was…
Opinion: Yes, everyone should get an updated Covid-19 vaccine
Last month, the Centers for Disease Control and Prevention recommended that everyone in the U.S….
STAT+: Like a vampire, some cancer cells can suck the energy source from immune cells
As elite hunters of the immune system, T cells are constantly prowling our bodies for…
Listen: Merger Mondays, Ozempic panic, & CRISPR’d pigs
When is a billion-dollar deal a bad omen? Has Wall Street gone overboard on Ozempic?…
STAT+: Scientists have mapped the human brain in unprecedented detail. They’re just getting started
The brain remains both the body’s most important organ and its least understood. But a…
STAT+: Better Therapeutics data on apps’ benefit with GLP-1s, Orexo hits a snag
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology…
Cell and gene therapies could be a safer bet than other drugs
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Life sciences deals on track to hit lowest point since 2017; EU regulators order Illumina to divest Grail
Good morning, everyone, and welcome to another busy day. We are scrambling, in fact, to…